Skip to main content
Vyome Holdings, Inc logo

Vyome Holdings, Inc — Investor Relations & Filings

Ticker · HIND ISIN · US67424L2097 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2023-08-25 Capital/Financing Update
Country US United States of America
Listing US HIND

About Vyome Holdings, Inc

https://www.reshapelifesciences.com/oba…

Vyome Holdings, Inc. is a clinical-stage biotechnology company focused on developing a portfolio of assets for immuno-inflammatory and potential orphan diseases. The company utilizes an artificial intelligence (AI)-driven platform to accelerate its research and development pipeline. Its operations are structured to leverage innovation and R&D capabilities across both the United States and India.

Recent filings

Filing Released Lang Actions
S-1 Filing
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the offering of securities by ReShape Lifesciences Inc. The text includes detailed information about the offering, risk factors, company description, market opportunity, and plan of distribution. This type of filing is related to capital raising activities and financing, specifically the registration of securities for public offering. It is not an annual report, earnings release, or any other type of report but a capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual filing, not just an announcement.
2023-08-25 English
10-Q Filing
Interim / Quarterly Report Q2 2023
2023-08-07 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the three and six months ended June 30, 2023. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 3885 characters, which is relatively short and primarily serves to announce the earnings release rather than provide the full report. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2023-08-07 English
4 Filing
Director's Dealing
2023-07-19 English
4 Filing
Director's Dealing
2023-07-06 English
S-8 Filing
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by ReShape Lifesciences Inc. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans. The text includes details about the 2022 Equity Incentive Plan, incorporation by reference of prior filings (10-K, 10-Q, 8-K), and legal indemnification provisions. It is not an annual report, earnings release, or other financial report but a registration statement for securities issuance under an employee plan. Therefore, it fits the category of a regulatory filing related to securities registration, which is best classified under Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a proxy statement, but a formal SEC filing for registration purposes.
2023-06-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.